When is this exam indicated?
Bone metastases of castration-resistant prostate cancer.
How is it performed?
Ra-223 is administered intravenously by slow injection (generally up to 1 minute) at intervals of 4 weeks ± 7 days for 6 injections. Unless clinical necessary, discharge will be within the same day. The most frequently observed adverse reactions (≥10%) in patients treated with Ra-223 were diarrhea, nausea, vomiting, and thrombocytopenia. The most serious adverse reactions were thrombocytopenia and neutropenia. Hypersensitivity reactions including anaphylactic and anaphylactoid allergic reactions are also possible, although they occur rarely.
There are no known contraindications to the use of Ra-223.